Tianlong Highlights Molecular Diagnostics and Blood Screening Solutions at ADLM 2026

By LabMedica International staff writers
Posted on 29 Jul 2026

Tianlong Science and Technology is participating in the ADLM 2026 Clinical Lab Expo, taking place July 28–30 in Anaheim, California. At booth 1047, the company is presenting molecular diagnostic and blood-screening solutions, including the Panall X1600, Genesys Sp96, Aurora PANA X6, Panall 8000, and blood-screening reagents.

The Panall X1600 is a fully automated molecular diagnostic system that processes up to 16 samples and detects as many as 48 targets in a single run. Its two independently controlled modules allow laboratories to perform different assays simultaneously, while automation covers the workflow from sample processing through result generation.


Image: Tianlong is showcasing the the Panall 8000 All-In-One Molecular Diagnosis System at ADLM 2026 (Photo courtesy of Tianlong)

Tianlong is also showcasing the Genesys Sp96 Real-Time PCR System, which can be expanded from 96 to 384 wells through a replaceable module without requiring recalibration. The platform supports high-resolution melting analysis for applications such as mutation and single-nucleotide polymorphism detection.

For high-throughput blood screening, the Aurora PANA X6 automates original-tube loading, barcode scanning, capping and decapping, sample pooling, nucleic acid extraction, and PCR setup. The system processes up to 576 samples per run and incorporates directional airflow, ultraviolet disinfection, HEPA filtration, negative pressure, and other contamination-control features.

The Panall 8000 provides an integrated option for laboratories with lower sample volumes. It combines sample loading, nucleic acid extraction, PCR preparation, amplification, detection, and result analysis and can process up to eight samples simultaneously.

Tianlong is additionally presenting a real-time PCR blood-screening kit for the qualitative detection of hepatitis B virus DNA, hepatitis C virus RNA, HIV-1 RNA, and HIV-2 RNA in serum or plasma. The kit supports both individual testing and six-sample pooling and is available in prefilled and non-prefilled formats.

Through its ADLM 2026 exhibit, Tianlong is highlighting technologies designed to reduce manual handling, consolidate molecular workflows, and support testing volumes ranging from small batches to high-throughput blood screening.


Latest ADLM 2026 News